Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative Efficacy and Safety of Metformin-Empagliflozin-Sitagliptin vs. Metformin-Empagliflozin-Linagliptin as Initial Triple Therapy in Type 2 Diabetes Mellitus
NCT07452913Phase 4Enrolling by invitation
- Sponsor
- Bahria University
- Start
- Jan 2026
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of sitagliptin, linagliptin in type 2 diabetes mellitus (T2DM), sponsored by Bahria University. Started Jan 2026; status: enrolling by invitation.
02
Drugs
sitagliptinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07452913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07452913.